IGNITE KUH NRSA Training Core

点击翻译按钮获取中文摘要

Contact PD/PI: Okusa, Mark D. NRSA-Training-001 (883) NRSA TRAINING CORE ABSTRACT The Integrated Virginia Research Training Centers in Kidney, Urology and Hematology (IGNITE KUH) training program is being proposed to address an unmet need and major gap in prioritized research training through development and integration of a statewide research program in the Commonwealth of Virginia. The IGNITE KUH NRSA Training Core is an innovative and distinctive multi-institutional, multi-departmental program comprising a team of 65 outstanding faculty from the University of Virginia (UVA), Virginia Commonwealth University (VCU), and Virginia Polytechnic Institute and State University (VT) with primary research programs anchored in the basic research and clinical science of benign KUH diseases in six thematic areas: Systems Biology and Functional Genomics, Immunity and Inflammation, Biomedical Engineering, Nanotherapeutics and Drug Discovery, Clinical and Data Sciences, and Predictive Analytics. The NRSA Training Core leverages existing strengths in kidney and hematological disease research, uniting them with urological disease research in a cohesive, integrated and coordinated research training program. The NRSA Training Core will be enhanced through participation and integration of the Translational Health Research Institute of Virginia (iTHRIV), a component of the Clinical and Translational Science Award (CTSA) partnership between UVA and VT, and the Wright Center for Clinical and Translational Research (CCTR) at VCU. Three major goals of the IGNITE KUH NRSA Training Core include: 1) increase training of PhD students, residents (urology) and postdoctoral fellows in basic and translational aspects of KUH in health and disease using a unified approach; 2) establish an integrated Virginia-wide research training program focused on KUH-diseases; and 3) attract outstanding students and postdoctoral fellows with long-term career interests in basic or clinical research into the IGNITE KUH Training Program. IGNITE KUH will prioritize strategies to attract students from underrepresented populations at several partner institutions, including three historically black universities in Virginia – Virginia State University (VSU), Hampton University (HU), and Virginia Union Universities (VUU) – thereby further enhancing development and training of both PhD researchers and physician scientists. The IGNITE KUH NRSA Training Core will address human health issues through increased education and training of the next generation of researchers and physician scientists in basic research or clinical science who can guide and lead future research programs aiming to lessen human disease and suffering in KUH-specific fields. Project Summary/Abstract Page 322 Contact PD/PI: Okusa, Mark D. NRSA-Training-001 (883) References 1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048-50. 2. Stapleton FB, Andreoli S, Ettenger R, Kamil E, Sedman A, Chesney R. Future workforce needs for pediatric nephrology: an analysis of the nephrology workforce and training requirements by the Workforce Committee of the American Society of Pediatric Nephrology. J Am Soc Nephrol 1997;8:S5-8. 3. Rosner MH, Berns JS. Transforming Nephrology. Clin J Am Soc Nephrol 2018;13:331-4. 4. de Boer IH. Nephrology at a Crossroads. Clin J Am Soc Nephrol 2018;13:324. 5. Lane CA, Brown MA. Nephrology: a specialty in need of resuscitation? Kidney Int 2009;76:594-6. 6. Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. JAMA Netw Open 2018;1:e184852. 7. McKibben MJ, Kirby EW, Langston J, et al. Projecting the Urology Workforce Over the Next 20 Years. Urology 2016;98:21-6. 8. Washington SL, 3rd, Baradaran N, Gaither TW, et al. Racial distribution of urology workforce in United States in comparison to general population. Transl Androl Urol 2018;7:526-34. 9. Woldu SL, Raj GV. Surgery: The surgeon-scientist - a dying breed? Nat Rev Urol 2016;13:698-9. 10. Keswani SG, Moles CM, Morowitz M, et al. The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists. Ann Surg 2017;265:1053-9. 11. Hougen HY, Lobo JM, Corey T, et al. Optimizing and validating the technical infrastructure of a novel tele- cystoscopy system. J Telemed Telecare 2016;22:397-404. 12. Sharma D, Wallace N, Levinsohn EA, et al. Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Adv 2019;3:3550-61. 13. Hoots WK, Abkowitz JL, Coller BS, DiMichele DM. Planning for the future workforce in hematology research. Blood 2015;125:2745-52. 14. Soffer E, Hoots WK. Challenges facing the benign hematology physician-scientist workforce: identifying issues of recruitment and retention. Blood Adv 2018;2:308. 15. Perry HM, Huang L, Ye H, et al. Endothelial Sphingosine 1Phosphate Receptor1 Mediates Protection and Recovery from Acute Kidney Injury. J Am Soc Nephrol 2016;27:3383-93. 16. Bajwa A, Huang L, Kurmaeva E, et al. Sphingosine Kinase 2 Deficiency Attenuates Kidney Fibrosis via IFN-gamma. J Am Soc Nephrol 2016;28:1145-61. 17. Bajwa A, Rosin DL, Chroscicki P, et al. Sphingosine 1-Phosphate Receptor-1 Enhances Mitochondrial Function and Reduces Cisplatin-Induced Tubule Injury. J Am Soc Nephrol 2014. 18. Bajwa A, Huang L, Ye H, et al. Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol 2012;189:2584-96. 19. Bajwa A, Jo SK, Ye H, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010;21:955-65. 20. Jo SK, Bajwa A, Ye H, et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int 2009;75:167-75. 21. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int 2008;73:1220-30. 22. Kao LP, Morad SAF, Davis TS, et al. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. J Lipid Res 2019;60:1590-602. 23. Gigliotti JC, Huang L, Ye H, et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013;24:1451-60. 24. Tanaka S, Inoue T, Hossack JA, Okusa MD. Nonpharmacological, Biomechanical Approaches to Control Inflammation in Acute Kidney Injury. Nephron 2017;137:277-81. 25. Gigliotti JC, Huang L, Bajwa A, et al. Ultrasound Modulates the Splenic Neuroimmune Axis in Attenuating AKI. J Am Soc Nephrol 2015;26:2407-81. 26. Chappell JC, Song J, Burke CW, Klibanov AL, Price RJ. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small 2008;4:1769-77. 27. Anderson AH, Xie D, Wang X, et al. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2020. References Cited Page 323